WHO ICTRP trial
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab…
CTIS2024-515407-19-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2024-515407-19-00 |
|---|---|
| Public title | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma |
| Scientific title | PANOVA-4: Pilot, Single arm Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - EF-39 |
| Primary sponsor | Novocure GmbH |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): Yes Therapeutic use - (Phase IV): No |
| Countries | Switzerland;Czechia;Germany;Spain |
| Conditions | Metastatic pancreatic ductal adenocarcinoma (mPDAC) MedDRA version: 27.0Level: LLTClassification code: 10033599Term: Pancreatic adenocarcinoma metastatic Class: 10029104;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] |
| Interventions | Product Name: Tecentriq 840 mg concentrate for solution for infusion, Product Code:PRD7537922, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: |
| Registration date | Dec 9, 2024 |
| Target size | 76 |
| Secondary IDs | NCT06390059;U1111-1309-1539;2022-003157-55 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: